secwatch.observer — SEC 8-K summary
======================================

Issuer:     Phathom Pharmaceuticals, Inc. (PHAT)
CIK:        0001783183
Form:       8-K
Filed at:   2023-05-10T23:59:59+00:00
Accession:  0001193125-23-140078
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Phathom Q1 net loss $37.8M, on track to resubmit Erosive GERD NDA this quarter
------------------------------------------------------------------------------

- Net loss $37.8M vs $40.7M YoY; operating expenses 36% lower than prior quarter due to cost controls after launch delay.
- Cash $129.6M at Mar 31, 2023; additional $100M term loan available, $175M upon FDA approval of VOQUEZNA for Erosive GERD.
- On track to resubmit Erosive GERD NDA this quarter; potential FDA approval and U.S. launch for Erosive GERD and H. pylori in Q4 2023.
- Ph3 PHALCON-NERD-301 trial met primary endpoint; regulatory submission for Non-Erosive GERD expected H2 2023.
- Coverage secured for 60% of commercial lives for VOQUEZNA TRIPLE PAK and DUAL PAK for H. pylori.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1783183/000119312523140078/0001193125-23-140078-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1783183/000119312523140078/d457235d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-140078

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer